Inadvertent ureteric placement and successful readjustment of a urodynamic catheter via fluoroscopy in a spinal injury patient
(Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - November 17, 2016 Category: Urology & Nephrology Authors: Floyd, M. S., Russell, H., Goodman, J., Vinod, C. P., Davies, M. C. Tags: Letter to the Editor Source Type: research
UroLift: a new minimally-invasive treatment for benign prostatic hyperplasia
‘UroLift’ has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - November 17, 2016 Category: Urology & Nephrology Authors: Jones, P., Rai, B. P., Aboumarzouk, O., Somani, B. K. Tags: Reviews Source Type: research
Sunitinib in the treatment of metastatic renal cell carcinoma
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy. Sunitinib alone causes signi...
Source: Therapeutic Advances in Urology - November 17, 2016 Category: Urology & Nephrology Authors: Schmid, T. A., Gore, M. E. Tags: Reviews Source Type: research
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI). It exerts inhibition of MET, vascular endothelial growth factor receptor type 2, AXL, and many other receptor tyro...
Source: Therapeutic Advances in Urology - November 17, 2016 Category: Urology & Nephrology Authors: Ruiz-Morales, J. M., Heng, D. Y. C. Tags: Reviews Source Type: research
Fasciocutaneous flap reinforcement of ventral onlay buccal mucosa grafts enables neophallus revision urethroplasty
Conclusions:
Our early results indicate that local or regional fasciocutaneous flaps enable ventral placement of BMGs for revision urethroplasty after phalloplasty. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - November 17, 2016 Category: Urology & Nephrology Authors: Wilson, S. C., Stranix, J. T., Khurana, K., Morrison, S. D., Levine, J. P., Zhao, L. C. Tags: Original Research Source Type: research
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
Renal cell carcinoma (RCC) is considered an immunogenic tumor with a prominent dysfunctional immune cell infiltrate, unable to control tumor growth. Cytokine-based immunotherapies, including interferon-α and interleukin-2, have been used for the treatment of metastatic RCC (mRCC). Long-term responses and complete remissions were observed, but durable clinical benefit efficacy in the overall population was limited and associated with significant toxicity. As a consequence, new generation agents targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways replaced interferon...
Source: Therapeutic Advances in Urology - August 24, 2016 Category: Urology & Nephrology Authors: Mennitto, A., Grassi, P., Ratta, R., Verzoni, E., Prisciandaro, M., Procopio, G. Tags: Reviews Source Type: research
Oxidation-reduction potential of semen: what is its role in the treatment of male infertility?
The diagnosis of male infertility relies largely on conventional semen analysis, and its interpretation has a profound influence on subsequent management of patients. Despite poor correlation between conventional semen parameters and male fertility potential, inclusion of advanced semen quality tests to routine male infertility workup algorithms has not been widely accepted. Oxidative stress is one of the major mediators in various etiologies of male infertility; it has deleterious effects on spermatozoa, including DNA damage. Alleviation of oxidative stress constitutes a potential treatment strategy for male infertility. ...
Source: Therapeutic Advances in Urology - August 24, 2016 Category: Urology & Nephrology Authors: Agarwal, A., Roychoudhury, S., Bjugstad, K. B., Cho, C.-L. Tags: Reviews Source Type: research
Management of equivocal (early) Fourniers gangrene
Conclusions:
Early exploration and debridement in equivocal (early) FG has a better clinical outcome with reduced hospital stay and number of debridement sessions than conservative treatment with delayed debridement. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - August 24, 2016 Category: Urology & Nephrology Authors: El-Shazly, M., Aziz, M., Aboutaleb, H., Salem, S., El-Sherif, E., Selim, M., Sultan, M., Omar, M., Abd Elbaky, T., Zanaty, F., Alenezi, T., Ghobashi, A., Allam, A. Tags: Original Research Source Type: research
Corrigendum to "Pazopanib in the treatment of advanced renal cell carcinoma" by David Cella and Jennifer L. Beaumont, Therapeutic Advances in Urology, 2016, Vol. 8(1) 61-69. DOI: 10.1177/1756287215614236
Page 65, column 2, lines 7–13
The following text did not appear correctly in the article:
"OS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while PFS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to Heng criteria, OS was NR/12 months while PFS was NR/25 months."
The correct text reads as follows:
"PFS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while OS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to ...
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Tags: Corrigendum Source Type: research
Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review
Renal angiomyolipomata associated with tuberous sclerosis complex are often bilateral, multiple and progressive. They cause significant morbidity and mortality in older children and adults. Surveillance and pre-emptive treatment reduce this risk. Recent research suggests treatment with mammalian target of rapamycin inhibitors is better at preventing bleeding, recurrence, and preserving renal function than percutaneous embolization. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Authors: Bissler, J. J., Kingswood, J. C. Tags: Reviews Source Type: research
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence
We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Authors: Hu, R., George, D. J., Zhang, T. Tags: Reviews Source Type: research
Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is an age-related phenomenon associated with prostatic enlargement and bladder outlet obstruction that can cause significant lower urinary tract symptoms (LUTS). These LUTS have a negative impact on an individual’s quality of life, which is why treatment of symptomatic BPH has become a major priority. Although surgical interventions exist for treating BPH, pharmacological therapies are often preferred due to their minimal invasiveness and high degree of effectiveness. The three classes of drugs approved for treating BPH include α-blockers, 5-α-reductase inhibitors (5-ARI...
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Authors: Olesovsky, C., Kapoor, A. Tags: Reviews Source Type: research
Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience
Erectile dysfunction (ED) is a very common disorder with a deep impact on quality of life on both patients and partners. Several options are available for treating ED: oral pharmacotherapy with phosphodiesterase 5 (PDE5) inhibitors currently represents the first-line option for many patients with ED. Alprostadil, a prostaglandin, has been marketed for many years as a urethral stick and an intracavernous injection for the treatment of ED. It is now available in the form of a cream (Vitaros/Virirec), a noninvasive treatment which combines an active drug (alprostadil, a synthetic prostaglandin E1) with a skin enhancer improvi...
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Authors: Cuzin, B. Tags: Reviews Source Type: research
Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial
Conclusion:
As a result of this study, under the control of the objective functional state of LUT, the influence of various factors on the patients’ stability in the treatment with AM drugs was revealed. (Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - July 5, 2016 Category: Urology & Nephrology Authors: Kosilov, K. V., Loparev, S., Kuzina, I., Shakirova, O., Zhuravskaya, N., Lobodenko, A. Tags: Original Research Source Type: research
Diseases masking and delaying the diagnosis of urogenital tuberculosis
(Source: Therapeutic Advances in Urology)
Source: Therapeutic Advances in Urology - May 9, 2016 Category: Urology & Nephrology Authors: Altez-Fernandez, C., Seas, C., Zegarra, L., Ugarte-Gil, C. Tags: Letter to the Editor Source Type: research
